HCHF
13.5.2020 23:03:10 CEST | Business Wire | Press release
In response to the Higher Committee of Human Fraternity (HCHF) calls to pray for humanity today, 14th May, people of all races, colours, ethnicities, and nationalities stood together in an unprecedented event to pray and supplicate to God for an end to the COVID-19 pandemic, and to guide and inspire scientists find a vaccine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005852/en/
From the very first moment the HCHF announced its great initiative, the call gained the blessing and support of the two most prominent religious leaders in the world; His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Pope of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all the world.
Judge AbdelSalam, Secretary-General of the HCHF, held an online press conference on Monday, attended by Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis, and Irina Bokova, Former Director General of UNESCO during which he announced the details of the initiative in the presence of local and international media outlets.
Judge Mohamed AbdelSalam stated: “This support for the initiative is clear evidence that we can, especially when addressing common challenges, put aside our disagreements under the banner of our human fraternity. Believing that our common human values is the driving force for the HCHF’s members to announce the call to pray, fast and perform charitable work to rid mankind of this pandemic and its consequences.”
Judge AbdelSalam also announced the launch of the official website of the ‘Pray for Humanity’ initiative (pray.forhumanfraternity.org), which will provide live coverage of the day and will serve as a digital archive for this historic day and future events of the HCHF.
The HCHF was established to implement the humanitarian principles advocated by the Document on Human Fraternity and engage all religious and international organisations in this process to achieve peace, coexistence, global citizenship and human fraternity.
The HCHF consists of a group of influential figures of diverse religious and cultural backgrounds and experts in the fields of Inter-culture communication, interfaith dialogue and social coexistence:
- Cardinal Miguel Ángel Ayuso Guixot, President of the Pontifical Council for Interreligious Dialogue of the Holy See,
- Professor Mohamed Hussein Mahrasawi, President of Al-Azhar University,
- Judge Mohamed Mahmoud AbdelSalam, Former Advisor to the Grand Imam of Al-Azhar and the Secretary-General of the Committee,
- Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation,
- Irina Bokova, Former Director General of UNESCO,
- H.E. Mohamed Khalifa Al Mubarak, Chairman of the Department of Culture in Abu Dhabi,
- Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis,
- Dr. Sultan Al Remeithi, Secretary-General of the Muslim Council of Elders,
- Leymah Gbowee, a Liberian peace activist and Nobel Peace Laureate,
- Yasser Hareb, Emirati Writer and TV Presenter
- Father Professor Dr. Ioan Sauca, the Secretary-General of the World Council of Churches.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005852/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
